Skip to main content
Skip to main navigation
Search for :
Product Development Strategy
Early Clinical Development
Phase I/IIa Clinical Trials
Phase II/III Clinical Trials
Interventional Phase IIIb/Phase IV Clinical Trials
Observational Research & Registries
Product Launch & Management
Market Access Solutions
Strategic Sales Outsourcing
Biopharmaceutical Sales & Marketing
Healthcare Payers & Providers
Medical Device & Diagnostics
Public Health & Government
Central Nervous System
Diabetes & Endocrinology
Early Phase Oncology
Public Health Interest
Other Therapeutic Areas
Ethics & Compliance
Rethinking sales to identify, promote and prove real value
Accelerate your product with the largest commercial footprint in the industry – a global pharma sales infrastructure to fuel your success.
Delivering Value to Market
This paper examines the various options available to biotech companies as they look to commercialize their innovative products.
Stakeholder Value: Overcoming Complexity in the European Market
This paper advocates early planning to ensure the right data is gathered in clinical trials including real-world data collection.
Allume Launch Planning Solution
Allume™, provides the expertise, and real-world experience and access to the localized resources you need to achieve commercial success.
Outsourcing in a Changing Environment
Head of US Commercial operations at Quintiles, Daryl Gaugler, presented ways to build strategic value by going beyond tactical commercial outsourcing.
A Blueprint for Clinical / Commercial Convergence
Bio pharmaceutical companies must shift from two divergent paths to one that combines clinical and commercial resources.
Read white paper
Unlike a traditional pharma CSO, Quintiles integrates clinical and commercial strategy to prove unique value.
Balance your resourcing as your portfolio adjusts to pipeline, regulatory and market fluctuations.
Identify outcome and pricing requirements to demonstrate value to diverse stakeholders.
Multi-channel solutions offer new opportunities to use resources more cost-effectively.
Find out how
Quintiles Announces Completion of Initial Public Offering of 27,236,841 Shares of Common Stock
Quintiles Announces Pricing of Initial Public Offering
Quintiles Unlocks Path for Digital Patient Engagement
Harnessing the Power of the Digital Patient White Paper
Tomorrow’s Path to Improved Early-Phase Oncology Drug Development
Strategic Portfolio Management & New Influencers in R&D Decision-Making